106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2017 All rights reserved
Disclaimer
is pocket card is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket card does not purport to suggest
any particular course of medical treatment. Use of the practice guidelines and this resource are
voluntary. e practice guidelines and additional information are available at www.asco.org/
CRC-markers-guideline. Copyright © 2017 by American Society of Clinical Oncolog y.
All rights reserved.
ASCOCOL17022
Abbreviations
CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HR, hazard ratio; IHC,
immunohistochemistry; KRAS, Kirsten rat sarcoma viral oncogene homolog ; nm, nonmutated;
ns, nonsignificant; LOD, limit of detection; RAS, rat sarcoma viral oncogene homolog
Source
Sepulveda AR et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline
From the American Society for Clinical Patholog y, College of American Pathologists,
Association for Molecular Patholog y, and the American Society of Clinical Oncolog y. J Clin
Oncol. 2017 Feb 6: JCO2016719807. doi: 10.1200/JCO.2016.71.9807. [Epub ahead of print]
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, patient
versions, frequently asked questions, and other clinical tools and resources, is available at
www.asco.org/CRC-markers-guideline and www.asco.org/guidelineswiki
Recommendation Grading
Type
Strength of
Evidence Benefit/harm
Quality of
Evidence
S Strong
recommendation
C Convincing B Benefits
outweigh
harms
H High
R
Recommendation A Adequate H Harms
outweigh
benefits
I Intermediate
NR No
recommendation
Ina Inadequate B/H Benefits and
harms in
balance
L Low
EC Expert consensus
opinion
Ins Insufficient U Unknown Ins Insufficient
